Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse

Neuroscience Letters

Volumn 460, Issue 2, 2009, Pages 130-132

  Frota, Elizabeth Regina Comini ^a   Rodrigues, David Henrique ^a   Donadi, Eduardo Antonio ^b   Brum, Doralina G ^b   Maciel, Damacio Ramon Kaimen ^c   Teixeira, Antônio Lúcio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Brain derived neurotrophic factor; Multiple sclerosis; Neuroprotection; Neurotrophins

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DEMYELINATING DISEASE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE;

ADOLESCENT; ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; YOUNG ADULT;

EID: 67349243002     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.05.057     Document Type: Article

References (22)

1. Azoulay D., Urshansky N., and Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J. Neuroimmunol. 195 (2008) 186-193
2. Azoulay D., Vachapova V., Shihaman B., Miler A., and Karni A. Brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol. 167 (2005) 215-218
3. Bar-Or A. The immunology of multiple sclerosis. Semin. Neurol. 28 (2008) 29-45
4. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol. 252 Suppl. 5 (2005) 3-9
5. Castellano V., and White L.J. Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis. J. Neurol. Sci. 269 (2008) 85-91
6. D'Souza M., Kappos L., and Czaplinsk A. Reconsidering clinical outcomes in multiple sclerosis: relapses, impairment, disability and beyond. J. Neurol. Sci. 274 (2008) 76-79
7. Ebers G.C. Natural history of multiple sclerosis. Neurol. Sci. 21 Suppl. 2 (2000) 815-817
8. Hemmer B., Archelos J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Immunol. 3 (2002) 291-303
9. Hohlfeld R., Kerschensteiner M., Stadelmann C., Lassmann H., and Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 24 (2000) 161-166
10. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H., and Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 53 (2003) 292-304
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
12. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
13. Martin R., and Sospedra M. The immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
14. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Neurology 5 (2001) 121-127
15. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshanker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
16. Petereit H.F., Lindemann H., and Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult. Scler. 9 (2003) 16-20
17. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2 (2001) 24-32
18. Reichardt L.F. Neurotrophin-regulated signal pathways. Phil. Trans. R. Soc. B. 361 (2005) 1545-1564
19. Sarchielli P., Greco L., Stipa A., Floridi A., and Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J. Neuroimmunol. 32 (2001) 180-188
20. Sarchielli P., Zaffaroni M., Floridi A., Greco L., Candeliere A., Mattioni A., Tenaglia S., Di Filippo M., and Calabresi P. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult. Scler. 13 (2007) 313-331
21. Stadelmann C., Kerschensteiner M., Misgeld T., Brück W., Hohlfeld R., and Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 125 (2002) 75-85
22. Weinstock-Guttman B., Zivadinov R., Tamaño-Blanco M., Abdelrahman N., Badgett D., Durfee J., Hussein S., Feichter J., Patrick K., Benedict R., and Ramanathan M. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J. Neuroimmunol. 188 (2007) 167-174